Observational studyMedical mycology2022
Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010-2019: A retrospective observational study based on national surveillance data.
Observational study in Medical mycology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Systematic Review of Candidemia in Brazil: Unlocking Historical Trends and Challenges in Conducting Surveys in Middle-Income Countries.Mycopathologia · 2024Pooled it
- Evaluating the sensitivity of the Wako β-D-glucan assay for the diagnosis of candidemia caused by Candida parapsilosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Eco-friendly fabrication of vanadium nanoparticlesRSC advances · 2026Article
- Phenotypic and genotypic differences between bloodstream and non-bloodMicrobiology spectrum · 2026Article
- OvercomingFrontiers in antibiotics · 2026Review
- Article
- Comparative Clinical Characteristics and Outcomes of Candida (Candidozyma) auris vs. Non-C. auris Candidemia in Non-neutropenic Patients in South India.Mycopathologia · 2025Article
- Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Pathogens (Basel, Switzerland) · 2025Review
- Optimizing Micafungin Dosing in Patients with Critically Ill Candidemia and Trends ofDrug design, development and therapy · 2025Article
- The first prevalence and antifungal susceptibility profile of Candida infections in Palestine, 2022.BMC infectious diseases · 2024Article
- Unresolved issues in the diagnosis of catheter related candidemia: A position paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Epidemiology of Invasive Candidiasis.Clinical epidemiology · 2024Review
- Candida parapsilosis complex in the clinical setting.Nature reviews. Microbiology · 2024Review
- Study of Candidemia and its Antifungal Susceptibility Profile at the University Hospital of Montevideo, Uruguay.Mycopathologia · 2023Article
- The Epidemiology and Clinical Characteristics of Fungemia in a Tertiary Hospital in Southern China: A 6-Year Retrospective Study.Mycopathologia · 2023Article
- Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.Medical mycology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The increasing incidence of candidemia and the emergence of drug-resistant Candida species are major concerns worldwide. Therefore, long-term surveillance studies are required. Here, we provide one of the largest longitudinal overviews of the trends in the prevalence of Candida species using national data of 57 001 candidemia isolates obtained from > 2000 hospitals for the 2010-2019 period in the Japan Nosocomial Infections Surveillance database. The proportion of Candida species, except Candida krusei and Candida guilliermondii, was almost the same during the study period. The proportion of C. guilliermondii surpassed that of C. krusei in 2014. The incidence of candidemia due to C. albicans (P < 0.0001), C. parapsilosis (P = 0.0002), and C. tropicalis (P < 0.0001) have decreased significantly over this period. Azole susceptibility of C. tropicalis was low, with 17.8% of isolates resistant to fluconazole and 13.5% resistant to voriconazole. The micafungin susceptibility of C. glabrata was low, with 8.0% of isolates showing resistance. The resistance rate of C. krusei toward amphotericin B fluctuated considerably (between 3.2% and 35.7%) over this period. The incidence rate of candidemia caused by C. parapsilosis and C. guilliermondii in hospitals responsible for bone marrow transplantation was significantly higher than that in other hospitals. Overall, our study suggests that in Japan, the species distribution of Candida was almost the same in this period and similar to that reported in North America and Europe. A relatively high resistance to azoles and micafungin was observed in C. glabrata, C. tropicalis, and C. krusei isolates, which require continued surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.